CGEM News and Press, Cullinan Oncology Inc. From 03/27/23

2023-03-27 14:17:01 ET Cullinan Oncology ( NASDAQ: CGEM ) announced Monday that the FDA cleared its Investigational New Drug (IND) application for cancer therapy CLN-617, marking the second such regulatory action to favor the company this year. Designed to function in the ...

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) ap...

2023-03-23 08:36:09 ET ORIC Pharmaceuticals ( NASDAQ: ORIC ) added ~5% pre-market Thursday after H.C. Wainwright upgraded the cancer-focused biotech to Buy from Neutral, adding its solid tumor candidate ORIC-114 to the firm's valuation model. The upgrade comes as ORIC pr...

2023-03-09 09:13:47 ET Cullinan Oncology press release ( NASDAQ: CGEM ): Q4 GAAP EPS of -$0.59 beats by $0.08 . Cash and investments were $550.1 million as of December 31, 2022 Cullinan expects its cash resources to provide runway into 2026 based on its current ope...

Expanded clinical stage portfolio through licensing of U.S. rights to CLN-418 Received FDA clearance of IND application for CLN-978; submitted IND application for CLN-617 Initial clinical data updates for CLN-049 and CLN-619 on track for mid-2023 Potential for 6 clinical...

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will pr...

Summary Jiangsu Hengrui Pharma out-licensed US rights for a novel small-molecule EZH2 inhibitor in a $706 million agreement with Connecticut's Treeline Biosciences. A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pha...

Cullinan Oncology ( NASDAQ: CGEM ) signed a licensing agreement  to develop and commercialize Harbour BioMed's tumor therapy HBM7008 (CLN-418) in the U.S. Cullinan said CLN-418/HBM7008 is a B7H4 x 4-1BB bispecific immune activator developed from next-gen heavy chain only antibody...

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in th...

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will pa...